See more : B & S International Holdings Ltd. (1705.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Tiziana Life Sciences Ltd (TLSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tiziana Life Sciences Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Terrace Energy Corp. (TCRRF) Income Statement Analysis – Financial Results
- People Co., Ltd. (7865.T) Income Statement Analysis – Financial Results
- MedRx Co., Ltd (4586.T) Income Statement Analysis – Financial Results
- Karyopharm Therapeutics Inc. (KPTI) Income Statement Analysis – Financial Results
- Oki Electric Industry Co., Ltd. (OKIEY) Income Statement Analysis – Financial Results
Tiziana Life Sciences Ltd (TLSA)
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 56.00K | 92.00K | 64.00K | 405.00K | 116.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 24.00K | 209.00K | 40.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 45.00K | 72.00K | 40.00K | 196.00K | 76.00K | 54.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% | 80.36% | 78.26% | 62.50% | 48.40% | 65.52% | 54.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 8.11M | 12.96M | 13.21M | 5.99M | 2.91M | 4.34M | 4.67M | 2.96M | 6.29M | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | 412.00K | 737.00K | 826.00K | 745.00K | 457.00K | 326.00K | 580.00K | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
Other Expenses | 9.87M | 1.63M | 13.31M | 8.82M | 4.86M | 3.48M | 3.57M | 4.33M | 2.33M | 1.97M | 0.00 | 0.00 | 82.00K | -3.03M | -9.00K | -2.00K | 63.00K | 0.00 | 1.50M | 1.06M | 218.00K | 451.00K | 2.42M | 2.43M | 488.00K | 199.00K |
Operating Expenses | 17.98M | 14.59M | 27.37M | 30.04M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 790.00K | 1.59M | 2.33M | 2.50M | 2.24M | 1.52M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
Cost & Expenses | 17.98M | 14.59M | 27.37M | 28.03M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 801.00K | 1.61M | 2.35M | 2.71M | 2.28M | 1.57M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
Interest Income | 1.15M | 0.00 | 0.00 | 8.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 56.00K | 36.00K | 47.00K | 47.00K | 10.00K | 22.00K | 79.00K | 157.00K | 8.00K | 1.00K |
Interest Expense | 10.00K | 7.00K | 176.00K | 320.00K | 73.00K | 9.46K | 9.00K | 9.00K | 18.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 3.00K | 5.00K | 8.00K | 10.00K | 5.00K | 8.00K | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 96.00K | 51.00K | 141.00K | 89.76K | 198.00K | 12.61K | 11.00K | 8.00K | 0.00 | -794.00K | 3.00K | -195.00K | -489.00K | 0.00 | 238.00K | 300.00K | 59.00K | 133.00K | 33.00K | 20.00K | 32.00K | 21.00K | 20.00K | 25.00K | 1.00K | 1.00K |
EBITDA | -17.14M | -15.34M | -26.34M | -27.93M | -7.58M | -7.81M | -8.24M | -7.28M | -8.61M | -3.56M | -283.00K | -653.00K | -778.00K | -3.03M | -516.00K | -1.24M | -2.49M | -2.15M | -2.18M | -1.48M | -1.95M | -2.35M | -2.39M | -2.33M | -553.00K | -271.00K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 948.78% | 0.00% | -921.43% | -1,348.91% | -3,890.63% | -531.60% | -1,879.31% | -1,491.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -17.98M | -14.59M | -27.37M | -28.03M | -7.77M | -7.82M | -8.25M | -7.29M | -8.61M | -2.76M | -286.00K | -458.00K | -289.00K | -3.03M | -754.00K | -1.54M | -2.55M | -2.29M | -2.21M | -1.50M | -1.98M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,533.33% | 0.00% | 352.44% | 0.00% | -1,346.43% | -1,675.00% | -3,982.81% | -564.44% | -1,907.76% | -1,512.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 742.00K | -811.00K | 717.00K | -312.00K | -73.00K | -8.67K | -9.00K | -9.00K | -18.00K | -808.00K | 3.00K | -195.00K | 0.00 | 0.00 | -4.00K | 31.00K | -37.00K | -8.00K | -10.00K | -5.00K | -8.00K | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 |
Income Before Tax | -17.24M | -15.40M | -26.66M | -28.34M | -7.85M | -7.83M | -8.26M | -7.30M | -8.63M | -3.57M | -283.00K | -653.00K | -289.00K | 0.00 | -758.00K | -1.51M | -2.59M | -2.29M | -2.22M | -1.50M | -1.99M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 352.44% | 0.00% | -1,353.57% | -1,641.30% | -4,040.63% | -566.42% | -1,916.38% | -1,517.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 449.00K | 0.00 | -3.24M | -2.21M | -540.00K | -1.53M | -1.49M | -89.00K | 0.00 | -60.00K | -3.00K | 195.00K | 489.00K | 3.03M | -28.00K | -81.00K | -169.00K | -118.00K | -82.00K | -114.00K | -30.00K | -65.00K | -89.00K | -83.00K | 0.00 | 0.00 |
Net Income | -17.69M | -15.40M | -23.42M | -26.13M | -7.31M | -6.30M | -6.77M | -7.21M | -8.63M | -3.51M | -280.00K | -848.00K | -778.00K | -3.03M | -730.00K | -1.43M | -2.42M | -2.18M | -2.14M | -1.39M | -1.96M | -2.31M | -2.33M | -2.27M | -554.00K | -272.00K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,333.33% | 0.00% | 948.78% | 0.00% | -1,303.57% | -1,553.26% | -3,776.56% | -537.28% | -1,845.69% | -1,402.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
EPS Diluted | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
Weighted Avg Shares Out | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Weighted Avg Shares Out (Dil) | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Tiziana Life Sciences expands Phase 2 MS trial to additional top US medical institutions
Tiziana Life Sciences secures grant for ALS trial
Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
Tiziana Life Sciences secures funding to advance development of MS and Alzheimer's therapy
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
Tiziana Life Sciences reports promising preclinical results for novel combination therapy targeting obesity
Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research
Tiziana Life Sciences names new chief executive
Source: https://incomestatements.info
Category: Stock Reports